Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

Allos Ventures makes investing in early-stage companies look easy. National data shows it is not. According to a 2018 Harvard Business School study, 75 percent of venture-backed startups fail. So one ...

WESTMINSTER, Colo., Sep 25, 2009 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for ...

Allos Ventures, an Indianapolis-based venture capital firm focused on Midwest technology companies, announced Tuesday that it has raised $40 million for its latest fund, Allos III, and has begun ...

Spectrum Pharmaceuticals (NASDAQ: SPPI - News) and Allos Therapeutics, Inc. (NASDAQ: ALTH - News) today announced that they have signed a definitive agreement under which Spectrum will acquire all of ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) and Mundipharma International Corporation Limited (Mundipharma) today jointly announced that the companies have entered ...

HENDERSON, Nev. (AP) -- Spectrum Pharmaceuticals Inc. said Thursday it completed its acquisition of Allos Therapeutics Inc., giving the combined company a third approved drug. Spectrum said 90 percent ...

BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...

Novel use of Causal AI revives long-stalled development pathways across complex generics and next-generation medicines for chronic disease Allos bends the cost-risk curve of drug development and ...

(Allos) today announced that, on May 9, 2012, each had received from the Federal Trade Commission (FTC) a Request for Additional Information and Documentary Material (Second Request) under the ...